Standard BioTools Inc. Long-Term Debt
Standard BioTools Inc. (LAB) had Long-Term Debt of $0 as of 2012-12-31, per its 10-K filed 2013-03-12.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermDebtNoncurrent · last filed 2013-03-12
- 2012-12-31: Long-term Debt, Excluding Current Maturities $0.00.
- 2012-09-30: Long-term Debt, Excluding Current Maturities $0.00.
- 2012-06-30: Long-term Debt, Excluding Current Maturities $0.00.
- 2011-12-31: Long-term Debt, Excluding Current Maturities $1.22M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2012-12-31 | $0.00 10-K · filed 2013-03-12 |
| 2012-09-30 | $0.00 10-Q · filed 2012-11-09 |
| 2012-06-30 | $0.00 10-Q · filed 2012-08-14 |
| 2011-12-31 | $1.22M 10-K · filed 2013-03-12 |
| 2011-09-30 | $2.99M 10-Q · filed 2011-11-14 |
| 2011-06-30 | $4.70M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $10.14M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |